bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
== Archaic Hassuna == ‘Archaic Hassuna’ has been introduced more recently as a new period different to proto-Hassuna. This period is recorded to have a decrease in the concentration of dung in ceramic production and an increase in the use of two-layer slabs in construction, although they were used prior to this period. During this timeframe, pottery kilns start to show up in many sites. The changing patterns within pottery may also connect with an increase in cultural diffusion. The type site, Tell Hassuna, is also recorded to possess Archaic Hassuna artifacts. The time frame for this period was about 6300-6000 BC.
In broiler chickens, the use of lithium ascorbate from the 14th to the 42nd day of cultivation in the amount of 1, 5, 10 mg/kg of body weight increased the total protein in blood serum due to the increase in the globulin fraction, which indicates an increase in the protective functions of the body of chicken and is one of reasons for higher livestock safety (P<0.05). Lithium ascorbate was tested as a cerebroprotective agent in the model of ischemic stroke. The effect of lithium ascorbate was studied on a model of chronic alcohol intoxication, in which deviant behavior of animals is combined with irreversible degenerative changes in the liver and central nervous system (including demyelination of nerves). Lithium ascorbate at doses of 5, 10 and 30 mg/kg normalized behavioral responses in the open field and elevated plus maze tests. An increase in the dose of lithium ascorbate (10 mg/kg, 30 mg/kg) did not lead to a significant improvement in the studied parameters of the condition. Histological analysis showed that the use of lithium ascorbate minimized the level of ischemic damage to neurocytes to the level of a reversible state and contributed to the preservation of the myelin sheaths of nerves.
=== RNA genomes === Like DNA, RNA can carry genetic information. RNA viruses have genomes composed of RNA that encodes a number of proteins. The viral genome is replicated by some of those proteins, while other proteins protect the genome as the virus particle moves to a new host cell. Viroids are another group of pathogens, but they consist only of RNA, do not encode any protein and are replicated by a host plant cell's polymerase.
The Seven Years' War (1756–1763) was fought across all of North America, Europe, Asia, Africa, and South America. Most of the great powers of the era participated, notably including the British Empire and French Empire, but polities from many continents played important roles. As a result, some historians describe it as the first global conflict, or as a world war. Historians like Richard F. Hamilton and Holger H. Herwig created a list of eight world wars, including the two generally agreed-upon world wars, the Seven Years' War, and five others: the Nine Years' War (1689–1697), the War of the Spanish Succession (1701–1714), the War of the Austrian Succession (1740–1748), the French Revolutionary Wars (1792–1802), and the Napoleonic Wars (1803–1815). British historian John Robert Seeley dubbed all of those wars between France and Great Britain (later the UK) between 1689 and 1815 (including the American Revolutionary War from 1775 to 1783) as the Second Hundred Years' War, echoing an earlier period of conflict between France and England known as the Hundred Years' War (1337–1453). Some writers have referred to the American Revolutionary War alone as a world war. Others (like William R. Thompson or Chase-Dunn and Sokolovsky) also include the Italian Wars and Dutch wars (Dutch-Spanish and Anglo-Dutch Wars) as part of Global Wars, while classifying WW1 and WW2 as the Global German Wars, and the Coalition Wars with Wars of Louis XIV as the 2nd and 1st Global French Wars.
== Fragile states == The Fragile States Index 2019, compiled by the NGO, Fund for Peace, ranked Thailand 77th in the world for fragility (178=least fragile; 1=most fragile). Finland topped the ranking; Yemen was at the bottom. Other ASEAN nations were ranked: Singapore, 162; Brunei, 124; Malaysia, 119; Vietnam, 109; Indonesia, 93; Laos, 62; Cambodia, 54; Philippines, 50; Myanmar, 22.
Sources: en.wikipedia.org
=== Surgical management === The following rhinoplastic techniques are applied to the surgical management of: (i) partial-thickness defects; (ii) full-thickness defects; (iii) heminasal reconstruction; and (iv) total nasal reconstruction.
=== Neurodegeneration === Several studies in cell and invertebrate models of Parkinson's disease (PD) and Huntington's disease (HD) suggested potential neuroprotective effects of SIRT2 inhibition, in striking contrast with other sirtuin family members. In addition, recent evidence shows that inhibition of SIRT2 protects against MPTP-induced neuronal loss in vivo.
=== Research applications === Ribosomal proteins: For the studies of individual ribosomal proteins, the use of proteins that are produced and purified from recombinant sources has largely replaced those that are obtained through isolation. However, isolation is still required for the studies of the whole ribosome. Lysosomal proteins: Lysosomal proteins are difficult to produce recombinantly due to the number and type of post-translational modifications that they have (e.g. glycosylation). As a result, recombinant lysosomal proteins are usually produced in mammalian cells. Plant cell culture was used to produce FDA-approved glycosylated lysosomal protein-drug, and additional drug candidates. Recent studies have shown that it may be possible to produce recombinant lysosomal proteins with microorganisms such as Escherichia coli and Saccharomyces cerevisiae. Recombinant lysosomal proteins are used for both research and medical applications, such as enzyme replacement therapy.
== Biological origin == Isoprenoid GDGTs originate as archaeal membrane lipids, whose fatty acids are converted to glycerol via esterification (ether lipid). They were first recognized as being associated with extremophilic archaea, but research in recent decades has discovered the compounds in a wide range of mesophilic environments as well, including soils, lake sediment, and marine deposits. Archaeal phylogenetic classes Nitrososphaerota (formerly Thaumarchaeota), Thermoproteota (formerly Crenarchaeota), "Euryarchaeota", and "Korarchaeota" produce GDGTs. Branched GDGTs are most commonly detected in peats and soils and are most associated with terrestrial settings. To date, no direct evidence for an unequivocal source organism has been reported, but the structural similarity of acidobacterial lipid to brGDGT alkyl chains strongly suggests that acidobacteriota synthesize brGDGT. The stereochemistry strongly hints at a non-archaeal origin.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.